Consultant Medical Oncologist, Princess Alexandra Hospital (PAH)/Queensland University of Technology, Brisbane, Australia
Prof Kenneth O’Byrne is a Consultant Medical Oncologist at Princess Alexandra Hospital (PAH) and Queensland University of Technology having recently arrived from St James’s Hospital (SJH) and Trinity College, Dublin. He qualified from University College, Dublin (UCD) in 1984, completed his higher professional oncology training at the Churchill Hospital, Oxford 1997 and subsequently worked at the University Hospitals of Leicester NHS Trust and University of Leicester until returning to Dublin in November ’03. He has a Doctorate Degree in Medicine from UCD and is a Fellow of the Royal College of Physicians, Ireland and of the Royal Australian College of Physicians. He was clinical director of the HOPE directorate at SJH until stepping down on 30th June 2012 after his appointment in Brisbane.
Prof O’Byrne is a founder member and president of the British thoracic oncology group (BTOG) and British mesothelioma interest group (BMIG). He is also a co-founder and board member of the European thoracic oncology platform (ETOP). He is past-chair and current member of the International Association for the Study of Lung Cancer (IASLC) career development and fellowship committee. He has been on the scientific and/or education committee for the IASLC world conference for lung cancer since Tokyo 2000. He is part of the ESMO chest tumours faculty, was on the scientific committee for Madrid 2014 and was an invited speaker for the inaugural ESMO-Asia congress, 2015. He is on the program committees for the ELCC and IMiG meetings in 2016. Prof O’Byrne was an active member of the Irish society of medical oncology (ISMO) and the Irish clinical oncology research group (ICORG) chairing the lung cancer disease specific sub-group and remains a member of the all Ireland lung cancer forum (AILCF) and EORTC lung cancer group. Prof O'Byrne retains an adjunct chair at Trinity College and continues to work with the thoracic oncology research group at SJH campus focusing on cancer cell survival and drug resistance mechanisms as novel biomarkers and targets for therapy.
In Australia Prof O’Byrne and A/Prof Derek Richard are the directors of the cancer and aging research program (CARP) in the Translational Research Institute, on the PAH campus, Brisbane focused on DNA stability. He is an active member of the ALTG, ALF, GCCTI and MOGA and organised the inaugural Brisbane Cancer Conference in December 2014, now an annual event. Prof O’Byrne has protected intellectual property for a novel lung cancer diagnostic miRNA signature and Inhibitors of Apoptosis Protein (IAP) targeted novel small molecule SMAC mimetics, and just filed for novel class of anti-cancer agent with broad based anti-cancer activity in Brisbane. He is a co-founder of two biotech companies in Brisbane, Blue Sky Biosciences and CARP Pharmaceuticals. Throughout his career he has been PI, co-PI, funded investigator or collaborator on multiple research grants, including ~GB25M over the past 5 years. He also proposed and drove the initial efforts for the establishment of the Hope Foundation for Cancer Research charity in Leicester.
Finally, Prof O’Byrne has co-supervised/is co-supervising the Doctorate Degrees of Medicine and PhDs of a total of 32 students as well as Masters and Honours science students. He has been a recognised trainer for medical students and junior doctors including those in specialist training in medical oncology and has played a role in mentoring junior consultants, particularly those with an academic bent.Prof O’Byrne is past European Editor for Journal of Clinical Oncology stepping down in 2016, and is currently on the editorial boards for Lung Cancer, Lung Cancer Management, Translational Lung Cancer Research and Chinese Clinical Oncology, has edited 2 text books in thoracic oncology, published over 300 manuscripts in peer-reviewed books and journals and over 19,000 citations of his work with a H-score of 69 and a ResearchGate score of 49.22.